Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Inhibitors and Its Correlation with Metabolic Parameters

We investigated the role of soluble PD-L1 (sPD-L1) in non-small cell lung carcinoma (NSCLC) patients treated with immune checkpoint inhibitors (ICI) and analyzed its association with clinical outcomes and metabolic parameters by 18F-fluorodeoxyglucose positron emission tomography/computed tomography...

Descripción completa

Detalles Bibliográficos
Autores principales: Castello, Angelo, Rossi, Sabrina, Toschi, Luca, Mansi, Luigi, Lopci, Egesta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352887/
https://www.ncbi.nlm.nih.gov/pubmed/32471030
http://dx.doi.org/10.3390/cancers12061373

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352887/
https://www.ncbi.nlm.nih.gov/pubmed/32471030
http://dx.doi.org/10.3390/cancers12061373

Ejemplares similares